Publications by authors named "Jiashuo Chao"

Claim this Profile
D
Dynamic urinary proteomics integrates single-cell and spatial transcriptomics to reveal tumour microenvironment and predict immunotherapy response in biliary tract cancer.
Shanshan Wang, Zhengguang Guo, Boyu Sun, Kai Liu, Jiashuo Chao, Yunchao Wang

Gut· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FAD synthase confers ferroptosis resistance and restrains CD8 T cell recruitment in hepatocellular carcinoma.
Jiashuo Chao, Yuan Liang, Hao Wang, Ziyu Xun, Shanshan Wang

Nat Commun· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gut microbiota and metabolite signatures predict severe immune-related adverse events in advanced hepatobiliary cancers.
Chengpei Zhu, Dongya Zhang, Yunchao Wang, Chenchen Zhang, Shanshan Wang, Jiashuo Chao

J Adv Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer.
Yang Tan, Kai Liu, Chengpei Zhu, Shanshan Wang, Yunchao Wang, Jiashuo Chao

Cancer Immunol Immunother· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer.
Yang Tan, Kai Liu, Chengpei Zhu, Shanshan Wang, Yunchao Wang, Jiashuo Chao

Cancer Immunol Immunother· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness, safety, and biomarker analysis of lenvatinib plus toripalimab as chemo-free therapy in advanced intrahepatic cholangiocarcinoma: a real-world study.
Shanshan Wang, Jiashuo Chao, Hao Wang, Shuofeng Li, Yunchao Wang

Cancer Immunol Immunother· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conversion surgery intervention versus continued systemic therapy in patients with a response after PD-1/PD-L1 inhibitor-based combination therapy for initially unresectable biliary tract cancer: a retrospective cohort study.
Shanshan Wang, Yunchao Wang, Chengpei Zhu, Kai Liu, Jiashuo Chao

Int J Surg· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
POSTN cancer-associated fibroblasts determine the efficacy of immunotherapy in hepatocellular carcinoma.
Hao Wang, Yuan Liang, Zheng Liu, Rui Zhang, Jiashuo Chao

J Immunother Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer.
Chengpei Zhu, Yunchao Wang, Ruijuan Zhu, Shanshan Wang, Jingnan Xue, Jiashuo Chao

Biomark Res· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma.
Chengpei Zhu, Chenchen Zhang, Shanshan Wang, Ziyu Xun, Dongya Zhang, Jiashuo Chao

J Immunother Cancer· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiation Therapy With Combination Therapy of Immune Checkpoint Inhibitors and Antiangiogenic Therapy for Hepatocellular Carcinoma.
Cong Ning, Xinmu Zhang, Yanyu Wang, Xu Yang, Xiaobo Yang, Jiashuo Chao, Yunchao Wang

Int J Radiat Oncol Biol Phys· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma.
Nan Zhang, Xu Yang, Mingjian Piao, Ziyu Xun, Yunchao Wang, Jiashuo Chao

Biomark Res· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis.
Jiashuo Chao, Shanshan Wang, Hao Wang, Nan Zhang, Yunchao Wang

Cancer Immunol Immunother· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study.
Chengpei Zhu, Hu Li, Xiaobo Yang, Shanshan Wang, Yunchao Wang, Jiashuo Chao

Cancer Immunol Immunother· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting proteostasis network in osteoporosis: Pathological mechanisms and therapeutic implications.
Cong Ma, Ronghui Yu, Junhong Li, Jiashuo Chao, Ping Liu

Ageing Res Rev· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and safety of bevacizumab as a salvage therapy for patients with advanced hepatocellular carcinoma targeting immune tolerance.
Longhao Zhang, Jingnan Xue, Nan Zhang, Yunchao Wang, Xu Yang, Jiashuo Chao

Am J Cancer Res· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC.
Yunchao Wang, Nan Zhang, Jingnan Xue, Chengpei Zhu, Yanyu Wang, Jiashuo Chao

Front Immunol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined analysis of imaging tumor capsule with imaging tumor size guides the width of resection margin for solitary hepatocellular carcinoma.
Jia-Shuo Chao, Qi Zhu, De-Sheng Chen, Gui-Ming Chen, Xue-Qian Xie

Hepatobiliary Pancreat Dis Int· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case Report: Transarterial Chemoembolization in Combination With Tislelizumab Downstages Unresectable Hepatocellular Carcinoma Followed by Radical Salvage Resection.
Jiashuo Chao, Qi Zhu, Desheng Chen, Xiao An, Aiqun Liu

Front Oncol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dedifferentiation of hepatocellular carcinoma: molecular mechanisms and therapeutic implications.
Jiashuo Chao, Senlin Zhao, Hongcheng Sun

Am J Transl Res· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and validation of T-ARMS-PCR to detect CYP2C19*17 allele.
Chenxi Jin, Zhikun Li, Xiaodi Zheng, Kailin Shen, Jiashuo Chao

J Clin Lab Anal· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-transplant infection improves outcome of hepatocellular carcinoma patients after orthotopic liver transplantation.
Jia-Shuo Chao, Sen-Lin Zhao, Si-Wen Ou-Yang, Yong-Bing Qian, Ai-Qun Liu

World J Gastroenterol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MICA*049, not MICA*009, is associated with Behçet's disease in a Chinese population.
Weifeng Zhu, Yan Deng, Jiucun Wang, Xinjian Guo, Weifeng Ding, Jiashuo Chao

Sci Rep· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of Single-Tube Tri-Primer ARMS-PCR to Detect the NFKB1 ATTG Insertion/Deletion Polymorphism.
Jiashuo Chao, Lina Chai, Xiaolong Yin, Zhongqin Zhou, Suming Xu

Genet Test Mol Biomarkers· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis